BioCentury | Jun 24, 2020
Politics, Policy & Law

U.K. accepting applications for subscription-based antibiotic pilot

NHS England is calling for biopharmas to apply for a contract to supply an antibiotic via the U.K.’s pilot subscription program, which will pay manufacturers a flat annual rate over 10 years for access to...
BioCentury | Apr 10, 2020
Politics, Policy & Law

Piloting a new course to reimbursing antibiotics

The shockingly fast speed at which COVID-19 turned from a regional breakout to a global pandemic with no treatments has made it easy to imagine a similar epidemic arising from multi-drug resistant bacteria, adding new...
BioCentury | Mar 6, 2020

Biotechs cede ground to end wild week of trading

Biotechs will have to wait until next week to see if ongoing market volatility amid uncertainty related to the COVID-19 outbreak will allow Imara, the last company remaining in the NASDAQ IPO queue, to price...
BioCentury | Feb 21, 2020
Product Development

Gilead beefing up Corp Dev with new SVP role

Gilead is creating an SVP of corporate development position, a signal to investors that the company is answering the call for increased M&A. According to a posting on several recruitment sites, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Feb 10, 2020
Politics, Policy & Law

Trump budget request claims $135B in drug savings, calls for NIH cut that won’t happen, flatlines FDA

President Donald Trump’s FY21 budget includes provisions the administration says will save $135 billion in drug costs over 10 years. The White House recycled ideas it has proposed over the last two years but did...
BioCentury | Jan 4, 2020

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

Biotech indexes rose as much as 33% in 2019 despite gaining little value overall in the year’s first nine months, with a series of clinical catalysts and strong appetite for M&A and licensing deals fueling...
BC Extra | Dec 10, 2019
Clinical News

ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
Items per page:
1 - 10 of 664